These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

45 related articles for article (PubMed ID: 22346276)

  • 1. Cutaneous toxicities from targeted therapies used in oncology: Literature review of clinical presentation and management.
    Huynh Dagher S; Blom A; Chabanol H; Funck-Brentano E
    Int J Womens Dermatol; 2021 Dec; 7(5Part A):615-624. PubMed ID: 35024416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dermatologic conditions in women receiving systemic cancer therapy.
    Ferreira MN; Ramseier JY; Leventhal JS
    Int J Womens Dermatol; 2019 Dec; 5(5):285-307. PubMed ID: 31909148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of Dermatologic Complications of Lung Cancer Therapies.
    Pugliese SB; Neal JW; Kwong BY
    Curr Treat Options Oncol; 2015 Oct; 16(10):50. PubMed ID: 26338208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overview of current systemic management of EGFR-mutant NSCLC.
    Hsu WH; Yang JC; Mok TS; Loong HH
    Ann Oncol; 2018 Jan; 29(suppl_1):i3-i9. PubMed ID: 29462253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A case of cicatricial alopecia associated with erlotinib.
    Yang BH; Bang CY; Byun JW; Han SH; Song HJ; In SG; Shin JH; Choi GS
    Ann Dermatol; 2011 Dec; 23(Suppl 3):S350-3. PubMed ID: 22346276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonscarring inflammatory alopecia associated with the epidermal growth factor receptor inhibitor gefitinib.
    Graves JE; Jones BF; Lind AC; Heffernan MP
    J Am Acad Dermatol; 2006 Aug; 55(2):349-53. PubMed ID: 16844529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Adverse cutaneous reactions to erlotinib].
    Pitarch G; Garde J; Torrijos A; Juárez A; Febrer MI; Camps C
    Actas Dermosifiliogr; 2008; 99(1):54-60. PubMed ID: 18206087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erlotinib-related skin toxicities: treatment strategies in patients with metastatic non-small cell lung cancer.
    Kiyohara Y; Yamazaki N; Kishi A
    J Am Acad Dermatol; 2013 Sep; 69(3):463-72. PubMed ID: 23602600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perifollicular Xanthoma Occurring in Patients after Erlotinib Treatment.
    Kim EH; Kim DM; Lee JY
    Dermatol Ther (Heidelb); 2022 May; 12(5):1281-1286. PubMed ID: 35508798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Folliculitis decalvans associated with erlotinib.
    Hoekzema R; Drillenburg P
    Clin Exp Dermatol; 2010 Dec; 35(8):916-8. PubMed ID: 20456379
    [No Abstract]   [Full Text] [Related]  

  • 11. The role of anti-epidermal growth factor receptor and anti-vascular endothelial growth factor therapies in the treatment of non-small-cell lung cancer.
    Langer C; Soria JC
    Clin Lung Cancer; 2010 Mar; 11(2):82-90. PubMed ID: 20199973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A case report of inflammatory nonscarring alopecia associated with the epidermal growth factor receptor inhibitor erlotinib.
    Pongpudpunth M; Demierre MF; Goldberg LJ
    J Cutan Pathol; 2009 Dec; 36(12):1303-7. PubMed ID: 19519875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Skin toxicities associated with epidermal growth factor receptor inhibitors.
    Li T; Perez-Soler R
    Target Oncol; 2009 Apr; 4(2):107-19. PubMed ID: 19452131
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.